Assessing harm reduction services for drug users
Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who Use Drugs
This study is testing a new approach to help Black and Latinx individuals who use drugs get better support and services compared to the usual options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 3 sites (New Haven, Connecticut and 2 other locations) |
| Trial ID | NCT05776316 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of an integrated harm reduction intervention (IHRI) compared to standard harm reduction services in improving service utilization among Black and Latinx individuals who use drugs. Participants must be at least 18 years old and have misused opioids or other substances in the past 30 days. The study aims to provide insights into how tailored interventions can better serve marginalized communities affected by substance abuse. The research will be conducted across multiple locations, including NYU Langone Health and Yale University.
Who should consider this trial
Good fit: Ideal candidates are Black and Latinx individuals aged 18 and older who have misused opioids or other substances in the past month.
Not a fit: Patients with severe mental health issues, such as active suicidal ideation or unstable psychotic disorders, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance access to and effectiveness of harm reduction services for marginalized populations struggling with substance use.
How similar studies have performed: Other studies have shown promise in utilizing harm reduction approaches, but this integrated intervention is a novel application targeting specific racial and ethnic groups.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * at least 18 years of age * self-identified as misusing opioids +/- other substances (stimulants) in the past 30 days, confirmed by interview using DSM-5 criteria * English or Spanish speaking * able to provide informed consent. Exclusion Criteria: * inability to provide informed consent or participate in the study procedures as proposed in the consent * active suicidal or homicidal ideation or an unstable psychotic disorder (schizophrenia, schizoaffective disorder) or mood disorder (bipolar disorder, severe major depressive disorder) * an unwillingness to be randomized. * are prisoners
Where this trial is running
New Haven, Connecticut and 2 other locations
- Yale University — New Haven, Connecticut, United States (Recruiting)
- NYU Langone Health — New York, New York, United States (Not_yet_recruiting)
- Nathan Kline Institute — Orangeburg, New York, United States (Recruiting)
Study contacts
- Principal investigator: Ayana Jordan, MD, PhD — NYU Langone Health
- Study coordinator: Ayana Jordan, MD, PhD
- Email: Ayana.Jordan@nyulangone.org
- Phone: (203) 787-8032
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.